

Daiichi Sankyo to commercialize mRNA COVID-19 vaccine in Japan within 2022

26 October 2021 | News

Announces development progress of mRNA COVID-19 vaccine in Japan



Daiichi Sankyo has announced the progress of development of DS-5670, an mRNA vaccine in Japan, being evaluated against the novel coronavirus infectious disease (COVID-19), including results from a phase 1/2 clinical trial.

A non-clinical research project conducted in collaboration with the University of Tokyo's Institute of Medical Science showed that DS-5670 induced a neutralizing activity against previously designated Variant of Concerns, including the Delta variant.

Daiichi Sankyo plans to initiate a phase 2 clinical trial in November 2021 and a phase 3 clinical trial within FY2021, aiming for commercialization of DS-5670 in Japan within 2022.

In addition, in order to initiate a clinical trial of a supplemental booster for the vaccine (booster vaccine) in January 2022, Daiichi Sankyo is continuing discussions with the Japanese Ministry of Health, Labour and Welfare (MHLW), Pharmaceuticals and Medical Devices Agency (PMDA), and Japan Agency for Medical Research and Development (AMED).